Globus Medical Inc. (NYSE:GMED) saw a 38.9% surge last week, driven by bullish analyst ratings and stellar Q3 earnings. BofA Securities upgraded to a “buy” with a new $91 price target, while Wells Fargo set a $79 price target. Q3 net income rose 129% to $118.97 million.

GMED also raised its full-year revenue guidance to $2.86-$2.9 billion, showing confidence in continued growth. President and CEO Keith Pfeil emphasized a focus on innovation, execution, and delivering technologies that enhance patient outcomes. While GMED shows potential, some AI stocks may offer better returns with less risk.

Investors can explore other stock options that may double in three years or hidden AI stocks to buy now for potential growth opportunities. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Globus Medical (GMED) Soars 38.9% on Stellar Q3